2.55
-0.10 (-3.60%)
| Penutupan Terdahulu | 2.64 |
| Buka | 2.60 |
| Jumlah Dagangan | 266,106 |
| Purata Dagangan (3B) | 794,325 |
| Modal Pasaran | 205,054,832 |
| Harga / Pendapatan (P/E TTM) | 11.07 |
| Harga / Pendapatan (P/E Ke hadapan) | 55.87 |
| Harga / Jualan (P/S) | 2.82 |
| Harga / Buku (P/B) | 3.16 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2026 |
| Margin Keuntungan | 6.54% |
| Margin Operasi (TTM) | -40.99% |
| EPS Cair (TTM) | 0.050 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 169.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.58% |
| Nisbah Semasa (MRQ) | 2.49 |
| Aliran Tunai Operasi (OCF TTM) | 8.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.29 M |
| Pulangan Atas Aset (ROA TTM) | 3.53% |
| Pulangan Atas Ekuiti (ROE TTM) | 10.42% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Protalix BioTherapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | 2.5 |
| AI Insight | NA |
| Purata | 0.06 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 10.39% |
| % Dimiliki oleh Institusi | 10.22% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |